The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation

[1]  F. Foschi,et al.  Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study , 2017, Scientific Reports.

[2]  Peipei Xu,et al.  A systemic review and meta-analysis , 2017 .

[3]  Chao Lu,et al.  Retrospective study , 2016, Medicine.

[4]  T. Lazzarotto,et al.  Immunosuppression Modifications Based on an Immune Response Assay: Results of a Randomized, Controlled Trial , 2015, Transplantation.

[5]  L. Bolondi,et al.  Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[6]  A. Mancuso,et al.  Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[7]  M. Kasahara,et al.  Evaluation of the immune function assay in pediatric living donor liver transplantation , 2015, Pediatric transplantation.

[8]  N. André,et al.  Metronomics: towards personalized chemotherapy? , 2014, Nature Reviews Clinical Oncology.

[9]  J. H. Kim,et al.  Systemic Cytotoxic Chemotherapy of Patients With Advanced Hepatocellular Carcinoma in the Era of Sorafenib Nonavailability , 2014, Journal of clinical gastroenterology.

[10]  G. Brandi,et al.  Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. , 2013, The oncologist.

[11]  A. Mehrabi,et al.  Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation , 2013, Langenbeck's Archives of Surgery.

[12]  Luming Liu,et al.  Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. , 2013, World journal of gastroenterology.

[13]  F. Aucejo,et al.  Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation , 2013, Clinical transplantation.

[14]  L. Mariani,et al.  Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. , 2013, Journal of hepatology.

[15]  W. Bechstein,et al.  Recurrent hepatocellular carcinoma after liver transplantation – an emerging clinical challenge , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[16]  E. Vettorazzi,et al.  High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation , 2012, Transplant international : official journal of the European Society for Organ Transplantation.

[17]  A. Vitale,et al.  Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? , 2012, Transplantation proceedings.

[18]  Rhea Paul,et al.  Results of a randomized controlled trial of speech interventions for nonverbal preschoolers with ASD , 2012 .

[19]  P. Galle,et al.  Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[20]  B. Sangro,et al.  Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[21]  Patrick M M Bossuyt,et al.  Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. , 2012, The Lancet. Oncology.

[22]  F. Piscaglia,et al.  Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[23]  S. Zeuzem,et al.  mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation. , 2011, Journal of hepatology.

[24]  W. Cacheux,et al.  Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients , 2012, Investigational New Drugs.

[25]  W. Lau,et al.  Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation , 2010, Acta Pharmacologica Sinica.

[26]  G. Brandi,et al.  Durable Complete Response of Hepatocellular Carcinoma after Metronomic Capecitabine , 2010, Tumori.

[27]  Joong-Won Park,et al.  Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation , 2018, Journal of Korean medical science.

[28]  E. Cordero,et al.  Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation. , 2009, Transplantation proceedings.

[29]  Y. Bang,et al.  Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation , 2009, Journal of gastroenterology and hepatology.

[30]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[31]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[32]  M. Vivarelli,et al.  Liver Transplantation for Hepatocellular Carcinoma Under Calcineurin Inhibitors: Reassessment of Risk Factors for Tumor Recurrence , 2008, Annals of surgery.

[33]  I. Hozo,et al.  Estimating the mean and variance from the median, range, and the size of a sample , 2005, BMC medical research methodology.

[34]  W. Grigioni,et al.  Liver transplantation for hepatocellular carcinoma: Further considerations on selection criteria , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[35]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[36]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[37]  Mark W. Lipsey,et al.  Practical Meta-Analysis , 2000 .

[38]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[39]  R. Wiesner,et al.  Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome , 1998, Hepatology.

[40]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[41]  P. Lachenbruch.  Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[42]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[43]  J R Beck,et al.  A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. , 1982, The American journal of medicine.